ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma

ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma

In the just-concluded 65th American Society of Hematology (ASH) Annual Meeting, CAR-T therapy emerged as a crucial advancement in the treatment of Multiple Myeloma (MM). The only approved BCMA CAR-T in China, Idecabtagene Vicleucel (CT103A), shone brightly. Professor Chunrui Li and her team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, presented a study (abstract 761) reporting the efficacy and safety data of CT103A in refractory/relapsed MM, garnering widespread attention. "Tumor Insights" had the privilege of interviewing Professor Li at the event, delving deep into the advancements in MM treatment and future directions
Prof. Ma Jun Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

Prof. Ma Jun Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

Local time on December 9th, the eagerly awaited 65th American Society of Hematology (ASH) Annual Meeting officially kicked off in San Diego, USA. The Oncology Insight reporting team delved into the forefront, witnessing the impressive presence of "The Voice of China" on the international stage. ASH is one of the largest and most comprehensive international academic conferences in the field of hematology globally, attracting numerous experts and scholars from around the world each year, including a significant representation from China. On the second day of the conference, we had the privilege of interviewing Professor Ma Jun, a leading figure in the field of hematology in China and the Director of the Harbin Institute of Hematology and Oncology. He shared his insights and highlights of this year's conference. Below is Professor Ma Jun's perspective:
2023 ASH丨Professor Jiang Qian: Discussing Drug Resistance in Chronic Myeloid Leukemia (CML) Treatment and the Value of Novel TKIs

2023 ASH丨Professor Jiang Qian: Discussing Drug Resistance in Chronic Myeloid Leukemia (CML) Treatment and the Value of Novel TKIs

The 65th Annual Meeting of the American Society of Hematology (ASH) recently concluded, with significant contributions in the field of Chronic Myeloid Leukemia (CML) treatment. Professor Jiang Qian and her team from Peking University People's Hospital presented multiple studies, with abstracts 867 and 869 selected for oral presentations. These reports highlighted the potential of TGRX-678 and Olverembatinib in CML treatment and overcoming drug resistance. "Hematology Frontier" had the privilege of interviewing Professor Jiang Qian on these topics.